| Authors: |
Poggi G; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland., Portalés A; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland., Robert M; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland., Hofer C; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland., Schmid S; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland., Kúkeľová D; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland., Sigrist H; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland., Just S; Department of CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany., Hengerer B; Department of CNS Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany., Pryce CR; Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland; Neuroscience Center Zurich, Zurich, Switzerland. Electronic address: christopher.pryce@bli.uzh.ch. |
